Across TCGA pan-cancer cohorts, FRMD5 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FRMD5 data layer compared with 25 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FRMD5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FRMD5 expression acts as an unfavorable survival marker.
PDAC and GBM are the cancer types where FRMD5 mass-spec protein most reproducibly stratifies survival.